Identification
- Name
- Enzalutamide
- Accession Number
- DB08899 (DB05094)
- Type
- Small Molecule
- Groups
- Approved
- Description
Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
- Structure
- Synonyms
- Not Available
- External IDs
- MDV 3100 / MDV-3100 / MDV3100
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Xtandi Capsule 40 mg Oral Astellas Pharma Inc 2013-06-07 Not applicable Canada Xtandi Capsule 40 mg/1 Oral Astellas Pharma Inc 2012-08-31 Not applicable US Xtandi Capsule 40 mg Oral Astellas Pharma Europe Bv 2013-06-21 Not applicable EU - Categories
- Androgen Receptor Inhibitor
- Anti-Androgens
- Antineoplastic Agents
- Antineoplastic and Immunomodulating Agents
- Cytochrome P-450 CYP2B6 Inhibitors
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C8 Inhibitors
- Cytochrome P-450 CYP2C8 Substrates
- Cytochrome P-450 CYP2C9 Inducers
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A Inducers (strong)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inducers (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 Enzyme Inhibitors
- Endocrine Therapy
- Hormone Antagonists and Related Agents
- Hydantoins
- Imidazoles
- Imidazolidines
- Non-Steroidal Anti-Androgens
- P-glycoprotein/ABCB1 Inhibitors
- Thiohydantoins
- UNII
- 93T0T9GKNU
- CAS number
- 915087-33-1
- Weight
- Average: 464.436
Monoisotopic: 464.093009286 - Chemical Formula
- C21H16F4N4O2S
- InChI Key
- WXCXUHSOUPDCQV-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
- IUPAC Name
- 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide
- SMILES
- CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F
Pharmacology
- Indication
Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
- Structured Indications
- Pharmacodynamics
Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52.
- Mechanism of action
Enzalutamide is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume.
Target Actions Organism AAndrogen receptor inhibitorHuman - Absorption
The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours); Cmax, steady state, enzalutamide = 16.6 μg/mL; Cmax, steady state, N-desmethyl enzalutamide = 12.7 μg/mL; Time to steady state, daily dosing = 28 days;
- Volume of distribution
Apparent volume of distribution (Vd/F), single oral dose = 110 L
- Protein binding
Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins.
- Metabolism
Enzalutamide is hepatically metabolized, primarily by CYP2C8 and CYP3A4. The enzyme that converts enzalutamide to its active metabolite, N-desmethyl enzalutamide, is CYP2C8. The activity of N-desmethyl-enzalutamide is similar to that of the parent compound.
- Route of elimination
Enzalutamide is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).
- Half life
The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.
- Clearance
Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)
- Toxicity
The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Enzalutamide. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide. Experimental, Illicit 5-androstenedione The serum concentration of 5-androstenedione can be decreased when it is combined with Enzalutamide. Experimental, Illicit Abemaciclib The serum concentration of Abemaciclib can be decreased when it is combined with Enzalutamide. Approved, Investigational Abiraterone The serum concentration of Abiraterone can be decreased when it is combined with Enzalutamide. Approved Acenocoumarol The serum concentration of Acenocoumarol can be decreased when it is combined with Enzalutamide. Approved, Investigational Acetaminophen The serum concentration of Acetaminophen can be decreased when it is combined with Enzalutamide. Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Enzalutamide. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Enzalutamide. Experimental Adinazolam The serum concentration of Adinazolam can be decreased when it is combined with Enzalutamide. Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Enzalutamide. Approved Albendazole The serum concentration of Albendazole can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Alclometasone The serum concentration of Alclometasone can be decreased when it is combined with Enzalutamide. Approved Aldosterone The serum concentration of Aldosterone can be decreased when it is combined with Enzalutamide. Experimental, Investigational Alfentanil The serum concentration of Alfentanil can be decreased when it is combined with Enzalutamide. Approved, Illicit Alfuzosin The serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide. Approved, Investigational Aliskiren The serum concentration of Aliskiren can be decreased when it is combined with Enzalutamide. Approved, Investigational Allylestrenol The serum concentration of Allylestrenol can be decreased when it is combined with Enzalutamide. Approved Almotriptan The serum concentration of Almotriptan can be decreased when it is combined with Enzalutamide. Approved, Investigational Alogliptin The serum concentration of Alogliptin can be decreased when it is combined with Enzalutamide. Approved Alosetron The serum concentration of Alosetron can be decreased when it is combined with Enzalutamide. Approved, Withdrawn alpha-Tocopherol acetate The serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Enzalutamide. Approved Alprazolam The serum concentration of Alprazolam can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational Ambrisentan The serum concentration of Ambrisentan can be decreased when it is combined with Enzalutamide. Approved, Investigational Ambroxol The serum concentration of Ambroxol can be decreased when it is combined with Enzalutamide. Approved, Investigational Amcinonide The serum concentration of Amcinonide can be decreased when it is combined with Enzalutamide. Approved Aminophenazone The serum concentration of Aminophenazone can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Aminophylline The serum concentration of Aminophylline can be decreased when it is combined with Enzalutamide. Approved Amiodarone The serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be decreased when it is combined with Enzalutamide. Approved Amlodipine The serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide. Approved Amodiaquine The serum concentration of Amodiaquine can be increased when it is combined with Enzalutamide. Approved, Investigational Amprenavir The serum concentration of Amprenavir can be decreased when it is combined with Enzalutamide. Approved, Investigational Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Enzalutamide. Approved, Investigational, Withdrawn Androstenedione The serum concentration of Androstenedione can be decreased when it is combined with Enzalutamide. Experimental, Illicit Anecortave The serum concentration of Anecortave can be decreased when it is combined with Enzalutamide. Investigational anecortave acetate The serum concentration of anecortave acetate can be decreased when it is combined with Enzalutamide. Investigational Antipyrine The serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide. Approved, Investigational Apalutamide The serum concentration of Enzalutamide can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Apixaban can be decreased when it is combined with Enzalutamide. Approved Apremilast The serum concentration of Apremilast can be decreased when it is combined with Enzalutamide. Approved, Investigational Aprepitant The serum concentration of Aprepitant can be decreased when it is combined with Enzalutamide. Approved, Investigational Argatroban The serum concentration of Argatroban can be decreased when it is combined with Enzalutamide. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Artemether The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy. Approved Artemether The serum concentration of Artemether can be decreased when it is combined with Enzalutamide. Approved Asenapine The serum concentration of Asenapine can be decreased when it is combined with Enzalutamide. Approved Astemizole The serum concentration of Astemizole can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Asunaprevir The serum concentration of Asunaprevir can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Atamestane The serum concentration of Atamestane can be decreased when it is combined with Enzalutamide. Investigational Atazanavir The serum concentration of Atazanavir can be decreased when it is combined with Enzalutamide. Approved, Investigational Atomoxetine The metabolism of Enzalutamide can be decreased when combined with Atomoxetine. Approved Atorvastatin The serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide. Approved Avanafil The serum concentration of Avanafil can be decreased when it is combined with Enzalutamide. Approved Axitinib The serum concentration of Axitinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Azelastine The serum concentration of Azelastine can be decreased when it is combined with Enzalutamide. Approved Azithromycin The serum concentration of Azithromycin can be decreased when it is combined with Enzalutamide. Approved Banoxantrone The serum concentration of Banoxantrone can be decreased when it is combined with Enzalutamide. Investigational Baricitinib The serum concentration of Baricitinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide. Approved, Investigational Bedaquiline The serum concentration of Bedaquiline can be decreased when it is combined with Enzalutamide. Approved Benidipine The serum concentration of Benidipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Benzphetamine The serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide. Approved, Illicit Benzyl alcohol The serum concentration of Benzyl alcohol can be decreased when it is combined with Enzalutamide. Approved Betamethasone The serum concentration of Betamethasone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Enzalutamide. Approved, Investigational Bexarotene The serum concentration of Bexarotene can be decreased when it is combined with Enzalutamide. Approved, Investigational Bezafibrate The serum concentration of Bezafibrate can be decreased when it is combined with Enzalutamide. Approved, Investigational Bicalutamide The serum concentration of Bicalutamide can be decreased when it is combined with Enzalutamide. Approved Bictegravir The serum concentration of Bictegravir can be decreased when it is combined with Enzalutamide. Approved, Investigational Bisoprolol The serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide. Approved Blonanserin The serum concentration of Blonanserin can be decreased when it is combined with Enzalutamide. Approved, Investigational Boceprevir The serum concentration of Boceprevir can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Bortezomib The serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide. Approved, Investigational Bosentan The serum concentration of Bosentan can be decreased when it is combined with Enzalutamide. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Enzalutamide. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Brigatinib The serum concentration of Brigatinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Brinzolamide The serum concentration of Brinzolamide can be decreased when it is combined with Enzalutamide. Approved Brivaracetam The serum concentration of Brivaracetam can be decreased when it is combined with Enzalutamide. Approved, Investigational Bromazepam The serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational Bromocriptine The serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide. Approved, Investigational Brompheniramine The serum concentration of Brompheniramine can be decreased when it is combined with Enzalutamide. Approved Budesonide The serum concentration of Budesonide can be decreased when it is combined with Enzalutamide. Approved Bupivacaine The serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide. Approved, Investigational Buprenorphine The serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational, Vet Approved Bupropion The serum concentration of Bupropion can be decreased when it is combined with Enzalutamide. Approved Buspirone The serum concentration of Buspirone can be decreased when it is combined with Enzalutamide. Approved, Investigational Busulfan The serum concentration of Busulfan can be decreased when it is combined with Enzalutamide. Approved, Investigational Cabazitaxel The serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide. Approved Cabergoline The serum concentration of Cabergoline can be decreased when it is combined with Enzalutamide. Approved Cabozantinib The serum concentration of Cabozantinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Caffeine The serum concentration of Caffeine can be decreased when it is combined with Enzalutamide. Approved Calcitriol The serum concentration of Calcitriol can be decreased when it is combined with Enzalutamide. Approved, Nutraceutical Canagliflozin The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide. Approved Cannabidiol The serum concentration of Cannabidiol can be decreased when it is combined with Enzalutamide. Approved, Investigational Carbamazepine The serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbinoxamine The serum concentration of Carbinoxamine can be decreased when it is combined with Enzalutamide. Approved Cariprazine The serum concentration of Cariprazine can be decreased when it is combined with Enzalutamide. Approved, Investigational Carvedilol The serum concentration of Carvedilol can be decreased when it is combined with Enzalutamide. Approved, Investigational Celecoxib The serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide. Approved, Investigational Celiprolol The serum concentration of Celiprolol can be decreased when it is combined with Enzalutamide. Approved, Investigational Cephalexin The serum concentration of Cephalexin can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide. Approved Cerivastatin The serum concentration of Cerivastatin can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Cevimeline The serum concentration of Cevimeline can be decreased when it is combined with Enzalutamide. Approved Chenodeoxycholic acid The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Enzalutamide. Approved Chlordiazepoxide The serum concentration of Chlordiazepoxide can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational Chloroquine The serum concentration of Chloroquine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Chlorphenamine The serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide. Approved Chlorpromazine The serum concentration of Chlorpromazine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Chlorzoxazone The serum concentration of Chlorzoxazone can be decreased when it is combined with Enzalutamide. Approved Cholecalciferol The serum concentration of Cholecalciferol can be decreased when it is combined with Enzalutamide. Approved, Nutraceutical Ciclesonide The serum concentration of Ciclesonide can be decreased when it is combined with Enzalutamide. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be decreased when it is combined with Enzalutamide. Approved, Investigational Cinacalcet The serum concentration of Cinacalcet can be decreased when it is combined with Enzalutamide. Approved Cisapride The serum concentration of Cisapride can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Citalopram The serum concentration of Citalopram can be decreased when it is combined with Enzalutamide. Approved Clarithromycin The serum concentration of Clarithromycin can be decreased when it is combined with Enzalutamide. Approved Clemastine The metabolism of Enzalutamide can be decreased when combined with Clemastine. Approved, Investigational Clindamycin The serum concentration of Clindamycin can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Clobazam The serum concentration of Clobazam can be decreased when it is combined with Enzalutamide. Approved, Illicit Clobetasol The serum concentration of Clobetasol can be decreased when it is combined with Enzalutamide. Approved, Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be decreased when it is combined with Enzalutamide. Approved Clobetasone The serum concentration of Clobetasone can be decreased when it is combined with Enzalutamide. Approved Clocortolone The serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide. Approved Clofazimine The serum concentration of Clofazimine can be decreased when it is combined with Enzalutamide. Approved, Investigational Clofibrate The serum concentration of Clofibrate can be decreased when it is combined with Enzalutamide. Approved, Investigational clomethiazole The serum concentration of clomethiazole can be decreased when it is combined with Enzalutamide. Investigational Clomipramine The serum concentration of Clomipramine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Clonazepam The serum concentration of Clonazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit Clonidine The serum concentration of Clonidine can be decreased when it is combined with Enzalutamide. Approved Clopidogrel The serum concentration of Clopidogrel can be decreased when it is combined with Enzalutamide. Approved Clorazepate The serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide. Approved, Illicit Clotiazepam The serum concentration of Clotiazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit Clotrimazole The metabolism of Enzalutamide can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The serum concentration of Clozapine can be decreased when it is combined with Enzalutamide. Approved Cobicistat The serum concentration of Enzalutamide can be increased when it is combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Cocaine The serum concentration of Cocaine can be decreased when it is combined with Enzalutamide. Approved, Illicit Codeine The serum concentration of Codeine can be decreased when it is combined with Enzalutamide. Approved, Illicit Colchicine The serum concentration of Colchicine can be decreased when it is combined with Enzalutamide. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Enzalutamide. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be decreased when it is combined with Enzalutamide. Approved Copanlisib The serum concentration of Copanlisib can be decreased when it is combined with Enzalutamide. Approved, Investigational Cortexolone 17α-propionate The serum concentration of Cortexolone 17α-propionate can be decreased when it is combined with Enzalutamide. Investigational Corticosterone The serum concentration of Corticosterone can be decreased when it is combined with Enzalutamide. Experimental Cortisone acetate The serum concentration of Cortisone acetate can be decreased when it is combined with Enzalutamide. Approved, Investigational Crisaborole The metabolism of Enzalutamide can be decreased when combined with Crisaborole. Approved, Investigational Crizotinib The serum concentration of Crizotinib can be decreased when it is combined with Enzalutamide. Approved Cyclobenzaprine The serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide. Approved Cyclophosphamide The serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide. Approved, Investigational Cyclosporine The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Enzalutamide. Experimental Cytarabine The serum concentration of Cytarabine can be decreased when it is combined with Enzalutamide. Approved, Investigational Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide. Approved Dabrafenib The serum concentration of Enzalutamide can be decreased when it is combined with Dabrafenib. Approved, Investigational Daclatasvir The serum concentration of Daclatasvir can be decreased when it is combined with Enzalutamide. Approved, Investigational Dantrolene The serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide. Approved, Investigational Dapagliflozin The serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide. Approved Dapsone The serum concentration of Dapsone can be decreased when it is combined with Enzalutamide. Approved, Investigational Darifenacin The serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide. Approved, Investigational Darunavir The serum concentration of Darunavir can be decreased when it is combined with Enzalutamide. Approved Dasabuvir The serum concentration of Dasabuvir can be decreased when it is combined with Enzalutamide. Approved Dasatinib The serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Daunorubicin The serum concentration of Daunorubicin can be decreased when it is combined with Enzalutamide. Approved Deferasirox The serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox. Approved, Investigational Deflazacort The serum concentration of Deflazacort can be decreased when it is combined with Enzalutamide. Approved, Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Enzalutamide. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Enzalutamide. Approved Desonide The serum concentration of Desonide can be decreased when it is combined with Enzalutamide. Approved, Investigational Desoximetasone The serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Enzalutamide. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Enzalutamide. Experimental, Vet Approved Desvenlafaxine The serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide. Approved, Investigational Deutetrabenazine The serum concentration of Deutetrabenazine can be decreased when it is combined with Enzalutamide. Approved, Investigational Dexamethasone The serum concentration of Dexamethasone can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Enzalutamide. Vet Approved Dexchlorpheniramine maleate The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Enzalutamide. Approved Dexlansoprazole The serum concentration of Dexlansoprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Dextromethorphan The serum concentration of Dextromethorphan can be decreased when it is combined with Enzalutamide. Approved Dextropropoxyphene The serum concentration of Dextropropoxyphene can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational, Withdrawn Diazepam The serum concentration of Diazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational, Vet Approved Diclofenac The serum concentration of Diclofenac can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Dienogest The serum concentration of Dienogest can be decreased when it is combined with Enzalutamide. Approved Diflorasone The serum concentration of Diflorasone can be decreased when it is combined with Enzalutamide. Approved Difluocortolone The serum concentration of Difluocortolone can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Difluprednate The serum concentration of Difluprednate can be decreased when it is combined with Enzalutamide. Approved Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide. Approved, Investigational Digoxin The serum concentration of Digoxin can be decreased when it is combined with Enzalutamide. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enzalutamide. Approved Dihydrocodeine The serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide. Approved, Illicit Dihydroergotamine The serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide. Approved, Investigational Diltiazem The serum concentration of Diltiazem can be decreased when it is combined with Enzalutamide. Approved, Investigational Disopyramide The serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide. Approved Disulfiram The serum concentration of Disulfiram can be decreased when it is combined with Enzalutamide. Approved Docetaxel The serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be decreased when it is combined with Enzalutamide. Approved, Investigational Dolasetron The serum concentration of Dolasetron can be decreased when it is combined with Enzalutamide. Approved, Investigational Domperidone The serum concentration of Domperidone can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Donepezil The serum concentration of Donepezil can be decreased when it is combined with Enzalutamide. Approved Dorzolamide The serum concentration of Dorzolamide can be decreased when it is combined with Enzalutamide. Approved Doxepin The serum concentration of Doxepin can be decreased when it is combined with Enzalutamide. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Enzalutamide. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be decreased when it is combined with Enzalutamide. Approved, Investigational Doxycycline The metabolism of Enzalutamide can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Dronabinol can be decreased when it is combined with Enzalutamide. Approved, Illicit Dronedarone The serum concentration of Dronedarone can be decreased when it is combined with Enzalutamide. Approved Dutasteride The serum concentration of Dutasteride can be decreased when it is combined with Enzalutamide. Approved, Investigational Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Enzalutamide. Approved Efavirenz The serum concentration of Efavirenz can be decreased when it is combined with Enzalutamide. Approved, Investigational Elbasvir The serum concentration of Elbasvir can be decreased when it is combined with Enzalutamide. Approved Eletriptan The serum concentration of Eletriptan can be decreased when it is combined with Enzalutamide. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be decreased when it is combined with Enzalutamide. Approved Elvitegravir The serum concentration of Elvitegravir can be decreased when it is combined with Enzalutamide. Approved Enalapril The serum concentration of Enalapril can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Enasidenib The serum concentration of Enasidenib can be decreased when it is combined with Enzalutamide. Approved, Investigational Epinastine The serum concentration of Epinastine can be decreased when it is combined with Enzalutamide. Approved, Investigational Eplerenone The serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide. Approved Equilenin The serum concentration of Equilenin can be decreased when it is combined with Enzalutamide. Experimental Equilin The serum concentration of Equilin can be decreased when it is combined with Enzalutamide. Approved Ergocalciferol The serum concentration of Ergocalciferol can be decreased when it is combined with Enzalutamide. Approved, Nutraceutical Ergoloid mesylate The serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide. Approved Ergonovine The serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide. Approved Ergotamine The serum concentration of Ergotamine can be decreased when it is combined with Enzalutamide. Approved Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Erythromycin The serum concentration of Erythromycin can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Escitalopram The serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide. Approved, Investigational Esomeprazole The serum concentration of Esomeprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Estazolam The serum concentration of Estazolam can be decreased when it is combined with Enzalutamide. Approved, Illicit Estradiol The serum concentration of Estradiol can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Estradiol acetate can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Estradiol benzoate The serum concentration of Estradiol benzoate can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Estradiol cypionate can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Estradiol dienanthate The serum concentration of Estradiol dienanthate can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Estradiol valerate can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Estramustine The serum concentration of Estramustine can be decreased when it is combined with Enzalutamide. Approved, Investigational Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Enzalutamide. Approved Estrone The serum concentration of Estrone can be decreased when it is combined with Enzalutamide. Approved Estrone sulfate The serum concentration of Estrone sulfate can be decreased when it is combined with Enzalutamide. Approved Eszopiclone The serum concentration of Eszopiclone can be decreased when it is combined with Enzalutamide. Approved, Investigational Ethanol The serum concentration of Ethanol can be decreased when it is combined with Enzalutamide. Approved Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enzalutamide. Approved Ethosuximide The serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide. Approved Ethylmorphine The serum concentration of Ethylmorphine can be decreased when it is combined with Enzalutamide. Approved, Illicit Etizolam The serum concentration of Etizolam can be decreased when it is combined with Enzalutamide. Approved Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Enzalutamide. Approved, Investigational Etoposide The serum concentration of Etoposide can be decreased when it is combined with Enzalutamide. Approved Etoricoxib The serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Enzalutamide. Approved Everolimus The serum concentration of Everolimus can be decreased when it is combined with Enzalutamide. Approved Exemestane The serum concentration of Exemestane can be decreased when it is combined with Enzalutamide. Approved, Investigational Famciclovir The serum concentration of Famciclovir can be decreased when it is combined with Enzalutamide. Approved, Investigational Felbamate The serum concentration of Felbamate can be decreased when it is combined with Enzalutamide. Approved Felodipine The serum concentration of Felodipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Fenofibrate The serum concentration of Fenofibrate can be decreased when it is combined with Enzalutamide. Approved Fentanyl The serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide. Approved Finasteride The serum concentration of Finasteride can be decreased when it is combined with Enzalutamide. Approved Fingolimod The serum concentration of Fingolimod can be decreased when it is combined with Enzalutamide. Approved, Investigational Flibanserin The serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide. Approved, Investigational Fluasterone The serum concentration of Fluasterone can be decreased when it is combined with Enzalutamide. Investigational Fluconazole The metabolism of Enzalutamide can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone The serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide. Approved, Investigational Flumethasone The serum concentration of Flumethasone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Flunisolide The serum concentration of Flunisolide can be decreased when it is combined with Enzalutamide. Approved, Investigational Flunitrazepam The serum concentration of Flunitrazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be decreased when it is combined with Enzalutamide. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Fluorometholone The serum concentration of Fluorometholone can be decreased when it is combined with Enzalutamide. Approved, Investigational Fluoxetine The serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Fluprednidene The serum concentration of Fluprednidene can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be decreased when it is combined with Enzalutamide. Approved Flurandrenolide The serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide. Approved Flurazepam The serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational Flutamide The serum concentration of Flutamide can be decreased when it is combined with Enzalutamide. Approved, Investigational Fluticasone furoate The serum concentration of Fluticasone furoate can be decreased when it is combined with Enzalutamide. Approved Fluticasone propionate The serum concentration of Fluticasone propionate can be decreased when it is combined with Enzalutamide. Approved Fluvastatin The serum concentration of Fluvastatin can be decreased when it is combined with Enzalutamide. Approved Fluvoxamine The metabolism of Enzalutamide can be decreased when combined with Fluvoxamine. Approved, Investigational Formestane The serum concentration of Formestane can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Fosamprenavir The serum concentration of Fosamprenavir can be decreased when it is combined with Enzalutamide. Approved Fosaprepitant The serum concentration of Enzalutamide can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Enzalutamide can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fulvestrant The serum concentration of Fulvestrant can be decreased when it is combined with Enzalutamide. Approved, Investigational Fusidic Acid The serum concentration of Enzalutamide can be increased when it is combined with Fusidic Acid. Approved, Investigational Galantamine The serum concentration of Galantamine can be decreased when it is combined with Enzalutamide. Approved Gefitinib The serum concentration of Gefitinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Gemfibrozil The serum concentration of Gemfibrozil can be decreased when it is combined with Enzalutamide. Approved Gitoformate Gitoformate may decrease the cardiotoxic activities of Enzalutamide. Experimental Glipizide The serum concentration of Glipizide can be decreased when it is combined with Enzalutamide. Approved, Investigational Glyburide The serum concentration of Glyburide can be decreased when it is combined with Enzalutamide. Approved Granisetron The serum concentration of Granisetron can be decreased when it is combined with Enzalutamide. Approved, Investigational Grazoprevir The serum concentration of Grazoprevir can be decreased when it is combined with Enzalutamide. Approved Grepafloxacin The serum concentration of Grepafloxacin can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Guanfacine The serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide. Approved, Investigational Halcinonide The serum concentration of Halcinonide can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Halofantrine The serum concentration of Halofantrine can be decreased when it is combined with Enzalutamide. Approved Haloperidol The serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide. Approved Halothane The serum concentration of Halothane can be decreased when it is combined with Enzalutamide. Approved, Vet Approved HE3286 The serum concentration of HE3286 can be decreased when it is combined with Enzalutamide. Investigational Hexobarbital The serum concentration of Hexobarbital can be decreased when it is combined with Enzalutamide. Approved Histamine The serum concentration of Histamine can be decreased when it is combined with Enzalutamide. Approved, Investigational Hydrocodone The serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide. Approved, Illicit Hydrocortisone The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Hydromorphone The serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide. Approved, Illicit Hydroxyprogesterone caproate The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Enzalutamide. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Enzalutamide. Approved Icotinib The serum concentration of Icotinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Idelalisib The serum concentration of Idelalisib can be decreased when it is combined with Enzalutamide. Approved Ifosfamide The serum concentration of Ifosfamide can be decreased when it is combined with Enzalutamide. Approved Iloperidone The serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide. Approved Imatinib The serum concentration of Imatinib can be decreased when it is combined with Enzalutamide. Approved Imidafenacin The serum concentration of Imidafenacin can be decreased when it is combined with Enzalutamide. Approved, Investigational Imipramine The serum concentration of Imipramine can be decreased when it is combined with Enzalutamide. Approved Imiquimod The serum concentration of Imiquimod can be decreased when it is combined with Enzalutamide. Approved, Investigational Indacaterol The serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide. Approved Indapamide The serum concentration of Indapamide can be decreased when it is combined with Enzalutamide. Approved Indinavir The serum concentration of Indinavir can be decreased when it is combined with Enzalutamide. Approved Ipratropium bromide The serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide. Approved Irbesartan The metabolism of Enzalutamide can be decreased when combined with Irbesartan. Approved, Investigational Irinotecan The serum concentration of Irinotecan can be decreased when it is combined with Enzalutamide. Approved, Investigational Isavuconazole The serum concentration of Isavuconazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Isavuconazonium The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Enzalutamide resulting in a loss in efficacy. Approved, Investigational Isosorbide Dinitrate The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide. Approved, Investigational Isosorbide Mononitrate The serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Enzalutamide. Approved Isradipine The serum concentration of Isradipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Istaroxime The serum concentration of Istaroxime can be decreased when it is combined with Enzalutamide. Investigational Itraconazole The serum concentration of Itraconazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be decreased when it is combined with Enzalutamide. Approved Ivacaftor The serum concentration of Ivacaftor can be decreased when it is combined with Enzalutamide. Approved Ivermectin The serum concentration of Ivermectin can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Ixabepilone The serum concentration of Ixabepilone can be decreased when it is combined with Enzalutamide. Approved, Investigational Ixazomib The serum concentration of Ixazomib can be decreased when it is combined with Enzalutamide. Approved, Investigational Ketamine The serum concentration of Ketamine can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Ketazolam The serum concentration of Ketazolam can be decreased when it is combined with Enzalutamide. Approved Ketobemidone The serum concentration of Ketobemidone can be decreased when it is combined with Enzalutamide. Approved, Investigational Ketoconazole The serum concentration of Ketoconazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Enzalutamide. Experimental Lansoprazole The serum concentration of Lansoprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Lapatinib The serum concentration of Lapatinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Laquinimod The serum concentration of Laquinimod can be decreased when it is combined with Enzalutamide. Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Enzalutamide. Approved Lenvatinib The serum concentration of Lenvatinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Lercanidipine The serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Letermovir The serum concentration of Enzalutamide can be increased when it is combined with Letermovir. Approved, Investigational Letrozole The serum concentration of Letrozole can be decreased when it is combined with Enzalutamide. Approved, Investigational Levobupivacaine The serum concentration of Levobupivacaine can be decreased when it is combined with Enzalutamide. Approved, Investigational Levocetirizine The serum concentration of Levocetirizine can be decreased when it is combined with Enzalutamide. Approved Levomethadyl Acetate The serum concentration of Levomethadyl Acetate can be decreased when it is combined with Enzalutamide. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be decreased when it is combined with Enzalutamide. Approved, Investigational Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Enzalutamide. Approved, Investigational Levothyroxine The serum concentration of Levothyroxine can be decreased when it is combined with Enzalutamide. Approved Lidocaine The serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Linagliptin The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide. Approved Lisuride The serum concentration of Lisuride can be decreased when it is combined with Enzalutamide. Approved, Investigational Lomitapide The serum concentration of Lomitapide can be decreased when it is combined with Enzalutamide. Approved, Investigational Loperamide The serum concentration of Loperamide can be decreased when it is combined with Enzalutamide. Approved Lopinavir The serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide. Approved Loratadine The serum concentration of Loratadine can be decreased when it is combined with Enzalutamide. Approved, Investigational Lorcaserin The serum concentration of Lorcaserin can be decreased when it is combined with Enzalutamide. Approved Lorpiprazole The serum concentration of Enzalutamide can be increased when it is combined with Lorpiprazole. Approved Losartan The serum concentration of Losartan can be decreased when it is combined with Enzalutamide. Approved Loteprednol The serum concentration of Loteprednol can be decreased when it is combined with Enzalutamide. Approved Lovastatin The serum concentration of Lovastatin can be decreased when it is combined with Enzalutamide. Approved, Investigational Luliconazole The serum concentration of Enzalutamide can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Enzalutamide can be decreased when it is combined with Lumacaftor. Approved Lumefantrine The serum concentration of Lumefantrine can be decreased when it is combined with Enzalutamide. Approved Lurasidone The serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide. Approved, Investigational Macimorelin The serum concentration of Macimorelin can be decreased when it is combined with Enzalutamide. Approved, Investigational Macitentan The serum concentration of Macitentan can be decreased when it is combined with Enzalutamide. Approved Maraviroc The serum concentration of Maraviroc can be decreased when it is combined with Enzalutamide. Approved, Investigational ME-609 The serum concentration of ME-609 can be decreased when it is combined with Enzalutamide. Investigational Mebendazole The serum concentration of Mebendazole can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Medical Cannabis The serum concentration of Medical Cannabis can be decreased when it is combined with Enzalutamide. Experimental Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide. Approved, Investigational Medrysone The serum concentration of Medrysone can be decreased when it is combined with Enzalutamide. Approved Mefloquine The serum concentration of Mefloquine can be decreased when it is combined with Enzalutamide. Approved, Investigational Melengestrol The serum concentration of Melengestrol can be decreased when it is combined with Enzalutamide. Vet Approved Meloxicam The serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Methadone The serum concentration of Methadone can be decreased when it is combined with Enzalutamide. Approved Methaqualone The serum concentration of Methaqualone can be decreased when it is combined with Enzalutamide. Illicit, Withdrawn Methoxsalen The serum concentration of Methoxsalen can be decreased when it is combined with Enzalutamide. Approved Methoxyflurane The serum concentration of Methoxyflurane can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Methylprednisolone The serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Methyltestosterone The serum concentration of Methyltestosterone can be decreased when it is combined with Enzalutamide. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Enzalutamide. Experimental Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Enzalutamide. Approved, Investigational Metronidazole The serum concentration of Metronidazole can be decreased when it is combined with Enzalutamide. Approved Mexiletine The serum concentration of Mexiletine can be decreased when it is combined with Enzalutamide. Approved, Investigational Mianserin The serum concentration of Mianserin can be decreased when it is combined with Enzalutamide. Approved, Investigational Mibefradil The serum concentration of Mibefradil can be decreased when it is combined with Enzalutamide. Investigational, Withdrawn Miconazole The serum concentration of Miconazole can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Midazolam The serum concentration of Midazolam can be decreased when it is combined with Enzalutamide. Approved, Illicit Midostaurin The serum concentration of Midostaurin can be decreased when it is combined with Enzalutamide. Approved, Investigational Mifepristone The serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide. Approved, Investigational Mirabegron The serum concentration of Mirabegron can be decreased when it is combined with Enzalutamide. Approved Mirtazapine The serum concentration of Mirtazapine can be decreased when it is combined with Enzalutamide. Approved Mitotane The serum concentration of Enzalutamide can be decreased when it is combined with Mitotane. Approved Modafinil The serum concentration of Modafinil can be decreased when it is combined with Enzalutamide. Approved, Investigational Mometasone The serum concentration of Mometasone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Montelukast The serum concentration of Montelukast can be decreased when it is combined with Enzalutamide. Approved Morphine The serum concentration of Morphine can be decreased when it is combined with Enzalutamide. Approved, Investigational Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Enzalutamide. Approved, Investigational Nabiximols The serum concentration of Nabiximols can be decreased when it is combined with Enzalutamide. Approved Naloxegol The serum concentration of Naloxegol can be decreased when it is combined with Enzalutamide. Approved Naloxone The serum concentration of Naloxone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Nateglinide The serum concentration of Nateglinide can be decreased when it is combined with Enzalutamide. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be decreased when it is combined with Enzalutamide. Investigational Nefazodone The serum concentration of Nefazodone can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Nelfinavir The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide. Approved Neratinib The serum concentration of Neratinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Netupitant The serum concentration of Netupitant can be decreased when it is combined with Enzalutamide. Approved, Investigational Nevirapine The serum concentration of Enzalutamide can be decreased when it is combined with Nevirapine. Approved Nicardipine The serum concentration of Nicardipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Nicotine The serum concentration of Nicotine can be decreased when it is combined with Enzalutamide. Approved Nifedipine The serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide. Approved Nilotinib The serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Nilvadipine The serum concentration of Nilvadipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Nimodipine The serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Nisoldipine The serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide. Approved Nitrazepam The serum concentration of Nitrazepam can be decreased when it is combined with Enzalutamide. Approved Nitrendipine The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide. Approved, Investigational Norethisterone The serum concentration of Norethisterone can be decreased when it is combined with Enzalutamide. Approved Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Enzalutamide. Approved Nortriptyline The serum concentration of Nortriptyline can be decreased when it is combined with Enzalutamide. Approved Odanacatib The serum concentration of Odanacatib can be decreased when it is combined with Enzalutamide. Investigational Olaparib The serum concentration of Olaparib can be decreased when it is combined with Enzalutamide. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Enzalutamide. Experimental, Investigational Oleoyl-estrone The serum concentration of Oleoyl-estrone can be decreased when it is combined with Enzalutamide. Investigational Olopatadine The serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide. Approved Omeprazole The serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Ondansetron The serum concentration of Ondansetron can be decreased when it is combined with Enzalutamide. Approved Opium The serum concentration of Opium can be decreased when it is combined with Enzalutamide. Approved, Illicit Orphenadrine The serum concentration of Orphenadrine can be decreased when it is combined with Enzalutamide. Approved Osimertinib The serum concentration of Osimertinib can be decreased when it is combined with Enzalutamide. Approved Ospemifene The serum concentration of Ospemifene can be decreased when it is combined with Enzalutamide. Approved, Investigational Ouabain Ouabain may decrease the cardiotoxic activities of Enzalutamide. Approved Oxazepam The serum concentration of Oxazepam can be decreased when it is combined with Enzalutamide. Approved Oxybutynin The serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide. Approved, Investigational Oxycodone The serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational Oxymorphone The serum concentration of Oxymorphone can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Paclitaxel The serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Palbociclib The serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide. Approved, Investigational Palonosetron The serum concentration of Palonosetron can be decreased when it is combined with Enzalutamide. Approved, Investigational Panobinostat The serum concentration of Panobinostat can be decreased when it is combined with Enzalutamide. Approved, Investigational Pantoprazole The serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide. Approved Paramethadione The serum concentration of Paramethadione can be decreased when it is combined with Enzalutamide. Approved Paramethasone The serum concentration of Paramethasone can be decreased when it is combined with Enzalutamide. Approved Parecoxib The serum concentration of Parecoxib can be decreased when it is combined with Enzalutamide. Approved Paricalcitol The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. Approved, Investigational Paritaprevir The serum concentration of Paritaprevir can be decreased when it is combined with Enzalutamide. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Enzalutamide. Approved Pentamidine The serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide. Approved, Investigational Pentobarbital The serum concentration of Enzalutamide can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel The serum concentration of Perampanel can be decreased when it is combined with Enzalutamide. Approved Pergolide The serum concentration of Pergolide can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved, Withdrawn Perhexiline The serum concentration of Perhexiline can be decreased when it is combined with Enzalutamide. Approved, Investigational Permethrin The serum concentration of Permethrin can be decreased when it is combined with Enzalutamide. Approved, Investigational Perospirone The serum concentration of Perospirone can be decreased when it is combined with Enzalutamide. Approved Perphenazine The serum concentration of Perphenazine can be decreased when it is combined with Enzalutamide. Approved Peruvoside Peruvoside may decrease the cardiotoxic activities of Enzalutamide. Experimental Pethidine The serum concentration of Pethidine can be decreased when it is combined with Enzalutamide. Approved Phenacetin The serum concentration of Phenacetin can be decreased when it is combined with Enzalutamide. Withdrawn Phenobarbital The serum concentration of Enzalutamide can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenoxybenzamine The serum concentration of Phenoxybenzamine can be decreased when it is combined with Enzalutamide. Approved Phenprocoumon The serum concentration of Phenprocoumon can be decreased when it is combined with Enzalutamide. Approved, Investigational Phenytoin The serum concentration of Enzalutamide can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pilocarpine The serum concentration of Pilocarpine can be decreased when it is combined with Enzalutamide. Approved, Investigational Pimecrolimus The serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide. Approved, Investigational Pimozide The serum concentration of Pimozide can be decreased when it is combined with Enzalutamide. Approved Pinacidil The serum concentration of Pinacidil can be decreased when it is combined with Enzalutamide. Approved Pioglitazone The serum concentration of Pioglitazone can be decreased when it is combined with Enzalutamide. Approved, Investigational Piperaquine The serum concentration of Piperaquine can be decreased when it is combined with Enzalutamide. Approved, Investigational Pipotiazine The serum concentration of Pipotiazine can be decreased when it is combined with Enzalutamide. Approved, Investigational Pitolisant The serum concentration of Pitolisant can be decreased when it is combined with Enzalutamide. Approved, Investigational Podofilox The serum concentration of Podofilox can be decreased when it is combined with Enzalutamide. Approved Pomalidomide The serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide. Approved Ponatinib The serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Posaconazole The serum concentration of Posaconazole can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Prasterone The serum concentration of Prasterone can be decreased when it is combined with Enzalutamide. Approved, Investigational, Nutraceutical Prasterone sulfate The serum concentration of Prasterone sulfate can be decreased when it is combined with Enzalutamide. Investigational Prasugrel The serum concentration of Prasugrel can be decreased when it is combined with Enzalutamide. Approved Pravastatin The serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide. Approved Prazepam The serum concentration of Prazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit Praziquantel The serum concentration of Praziquantel can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Prednicarbate The serum concentration of Prednicarbate can be decreased when it is combined with Enzalutamide. Approved, Investigational Prednisolone The serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be decreased when it is combined with Enzalutamide. Approved, Experimental, Investigational Primaquine The serum concentration of Primaquine can be decreased when it is combined with Enzalutamide. Approved Primidone The serum concentration of Enzalutamide can be decreased when it is combined with Primidone. Approved, Vet Approved Prochlorperazine The serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Progesterone The serum concentration of Progesterone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Proguanil The serum concentration of Proguanil can be decreased when it is combined with Enzalutamide. Approved Promazine The serum concentration of Promazine can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Propafenone The serum concentration of Propafenone can be decreased when it is combined with Enzalutamide. Approved Propiverine The serum concentration of Propiverine can be decreased when it is combined with Enzalutamide. Approved, Investigational Propofol The serum concentration of Propofol can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Propoxyphene napsylate The serum concentration of Propoxyphene napsylate can be decreased when it is combined with Enzalutamide. Approved Propranolol The serum concentration of Propranolol can be decreased when it is combined with Enzalutamide. Approved, Investigational Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Enzalutamide. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Enzalutamide. Approved Pyrazinamide The serum concentration of Pyrazinamide can be decreased when it is combined with Enzalutamide. Approved, Investigational Quazepam The serum concentration of Quazepam can be decreased when it is combined with Enzalutamide. Approved, Illicit Quetiapine The serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide. Approved Quinacrine The serum concentration of Quinacrine can be decreased when it is combined with Enzalutamide. Approved, Investigational Quinidine The serum concentration of Quinidine can be decreased when it is combined with Enzalutamide. Approved, Investigational Quinine The serum concentration of Quinine can be decreased when it is combined with Enzalutamide. Approved Rabeprazole The serum concentration of Rabeprazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Raloxifene The serum concentration of Raloxifene can be decreased when it is combined with Enzalutamide. Approved, Investigational Ramelteon The serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide. Approved, Investigational Ranolazine The serum concentration of Ranolazine can be decreased when it is combined with Enzalutamide. Approved, Investigational Reboxetine The serum concentration of Reboxetine can be decreased when it is combined with Enzalutamide. Approved, Investigational Regorafenib The serum concentration of Regorafenib can be decreased when it is combined with Enzalutamide. Approved Repaglinide The serum concentration of Repaglinide can be decreased when it is combined with Enzalutamide. Approved, Investigational Retapamulin The serum concentration of Retapamulin can be decreased when it is combined with Enzalutamide. Approved Ribociclib The serum concentration of Ribociclib can be decreased when it is combined with Enzalutamide. Approved, Investigational Rifabutin The serum concentration of Enzalutamide can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Enzalutamide can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Enzalutamide can be decreased when it is combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Enzalutamide. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Enzalutamide. Approved Rimexolone The serum concentration of Rimexolone can be decreased when it is combined with Enzalutamide. Approved Rimonabant The serum concentration of Rimonabant can be decreased when it is combined with Enzalutamide. Approved, Investigational Riociguat The serum concentration of Riociguat can be decreased when it is combined with Enzalutamide. Approved Risperidone The serum concentration of Risperidone can be decreased when it is combined with Enzalutamide. Approved, Investigational Ritonavir The serum concentration of Ritonavir can be decreased when it is combined with Enzalutamide. Approved, Investigational Rivaroxaban The serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide. Approved Rofecoxib The serum concentration of Rofecoxib can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Roflumilast The serum concentration of Roflumilast can be decreased when it is combined with Enzalutamide. Approved Rolapitant The serum concentration of Rolapitant can be decreased when it is combined with Enzalutamide. Approved, Investigational Romidepsin The serum concentration of Romidepsin can be decreased when it is combined with Enzalutamide. Approved, Investigational Ropinirole The serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide. Approved, Investigational Ropivacaine The serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide. Approved Rosiglitazone The metabolism of Enzalutamide can be decreased when combined with Rosiglitazone. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be decreased when it is combined with Enzalutamide. Approved Rotigotine The serum concentration of Rotigotine can be decreased when it is combined with Enzalutamide. Approved Roxithromycin The serum concentration of Roxithromycin can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Rucaparib The serum concentration of Rucaparib can be decreased when it is combined with Enzalutamide. Approved, Investigational Rupatadine The serum concentration of Rupatadine can be decreased when it is combined with Enzalutamide. Approved Ruxolitinib The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide. Approved Safinamide The serum concentration of Safinamide can be decreased when it is combined with Enzalutamide. Approved, Investigational Salmeterol The serum concentration of Salmeterol can be decreased when it is combined with Enzalutamide. Approved Saquinavir The serum concentration of Saquinavir can be decreased when it is combined with Enzalutamide. Approved, Investigational Sarilumab The therapeutic efficacy of Enzalutamide can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be decreased when it is combined with Enzalutamide. Approved Secobarbital The serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital. Approved, Vet Approved Selegiline The serum concentration of Selegiline can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Selexipag The serum concentration of Selexipag can be decreased when it is combined with Enzalutamide. Approved Seratrodast The serum concentration of Seratrodast can be decreased when it is combined with Enzalutamide. Approved Sertindole The serum concentration of Sertindole can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Sertraline The serum concentration of Sertraline can be decreased when it is combined with Enzalutamide. Approved Sevoflurane The serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Sibutramine The serum concentration of Sibutramine can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational, Withdrawn Sildenafil The serum concentration of Sildenafil can be decreased when it is combined with Enzalutamide. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Enzalutamide. Approved Siltuximab The serum concentration of Enzalutamide can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Simeprevir can be decreased when it is combined with Enzalutamide. Approved Simvastatin The serum concentration of Simvastatin can be decreased when it is combined with Enzalutamide. Approved Sirolimus The serum concentration of Sirolimus can be decreased when it is combined with Enzalutamide. Approved, Investigational Sitagliptin The serum concentration of Sitagliptin can be decreased when it is combined with Enzalutamide. Approved, Investigational Solifenacin The serum concentration of Solifenacin can be decreased when it is combined with Enzalutamide. Approved Sonidegib The serum concentration of Sonidegib can be decreased when it is combined with Enzalutamide. Approved, Investigational Sorafenib The serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide. Approved, Investigational Spiramycin The serum concentration of Spiramycin can be decreased when it is combined with Enzalutamide. Approved St. John's Wort The serum concentration of Enzalutamide can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Enzalutamide can be increased when it is combined with Stiripentol. Approved Sufentanil The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide. Approved, Investigational Sulfadiazine The serum concentration of Sulfadiazine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Sulfamethoxazole The serum concentration of Sulfamethoxazole can be decreased when it is combined with Enzalutamide. Approved Sulfinpyrazone The serum concentration of Sulfinpyrazone can be decreased when it is combined with Enzalutamide. Approved Sulfisoxazole The metabolism of Enzalutamide can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sunitinib The serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Suvorexant The serum concentration of Suvorexant can be decreased when it is combined with Enzalutamide. Approved, Investigational Synthetic Conjugated Estrogens, A The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enzalutamide. Approved Synthetic Conjugated Estrogens, B The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Enzalutamide. Approved Tacrolimus The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide. Approved, Investigational Tadalafil The serum concentration of Tadalafil can be decreased when it is combined with Enzalutamide. Approved, Investigational Tamoxifen The serum concentration of Tamoxifen can be decreased when it is combined with Enzalutamide. Approved Tamsulosin The serum concentration of Tamsulosin can be decreased when it is combined with Enzalutamide. Approved, Investigational Tasimelteon The serum concentration of Tasimelteon can be decreased when it is combined with Enzalutamide. Approved, Investigational Tasosartan The serum concentration of Tasosartan can be decreased when it is combined with Enzalutamide. Approved Taurochenodeoxycholic acid The serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Enzalutamide. Experimental Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Telithromycin The serum concentration of Telithromycin can be decreased when it is combined with Enzalutamide. Approved Temazepam The serum concentration of Temazepam can be decreased when it is combined with Enzalutamide. Approved, Investigational Temsirolimus The serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide. Approved Teniposide The serum concentration of Teniposide can be decreased when it is combined with Enzalutamide. Approved Terbinafine The serum concentration of Terbinafine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Terfenadine The serum concentration of Terfenadine can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Teriflunomide The metabolism of Enzalutamide can be decreased when combined with Teriflunomide. Approved Tesmilifene The serum concentration of Tesmilifene can be decreased when it is combined with Enzalutamide. Investigational Testosterone The serum concentration of Testosterone can be decreased when it is combined with Enzalutamide. Approved, Investigational Testosterone cypionate The serum concentration of Testosterone cypionate can be decreased when it is combined with Enzalutamide. Approved Testosterone enanthate The serum concentration of Testosterone enanthate can be decreased when it is combined with Enzalutamide. Approved Testosterone propionate The serum concentration of Testosterone propionate can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The serum concentration of Testosterone undecanoate can be decreased when it is combined with Enzalutamide. Approved, Investigational Tetracycline The serum concentration of Tetracycline can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Tezacaftor The serum concentration of Tezacaftor can be decreased when it is combined with Enzalutamide. Approved, Investigational Theophylline The serum concentration of Theophylline can be decreased when it is combined with Enzalutamide. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Enzalutamide. Approved, Withdrawn Thiotepa The serum concentration of Thiotepa can be decreased when it is combined with Enzalutamide. Approved, Investigational Tiagabine The serum concentration of Tiagabine can be decreased when it is combined with Enzalutamide. Approved, Investigational Ticagrelor The serum concentration of Ticagrelor can be decreased when it is combined with Enzalutamide. Approved Ticlopidine The serum concentration of Ticlopidine can be decreased when it is combined with Enzalutamide. Approved Tinidazole The serum concentration of Tinidazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Tiotropium The serum concentration of Tiotropium can be decreased when it is combined with Enzalutamide. Approved Tipranavir The serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be decreased when it is combined with Enzalutamide. Approved, Withdrawn Tocilizumab The serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab. Approved Tocofersolan The serum concentration of Tocofersolan can be decreased when it is combined with Enzalutamide. Approved Tocopherol The serum concentration of Tocopherol can be decreased when it is combined with Enzalutamide. Approved, Investigational Tofacitinib The serum concentration of Tofacitinib can be decreased when it is combined with Enzalutamide. Approved, Investigational Tolterodine The serum concentration of Tolterodine can be decreased when it is combined with Enzalutamide. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be decreased when it is combined with Enzalutamide. Approved Topiroxostat The metabolism of Enzalutamide can be decreased when combined with Topiroxostat. Approved, Investigational Topotecan The serum concentration of Topotecan can be increased when it is combined with Enzalutamide. Approved, Investigational Toremifene The serum concentration of Toremifene can be decreased when it is combined with Enzalutamide. Approved, Investigational Trabectedin The serum concentration of Trabectedin can be decreased when it is combined with Enzalutamide. Approved, Investigational Tramadol The serum concentration of Tramadol can be decreased when it is combined with Enzalutamide. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Enzalutamide. Approved, Investigational Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Enzalutamide. Approved, Investigational Trazodone The serum concentration of Trazodone can be decreased when it is combined with Enzalutamide. Approved, Investigational Tretinoin The serum concentration of Tretinoin can be decreased when it is combined with Enzalutamide. Approved, Investigational, Nutraceutical Triamcinolone The serum concentration of Triamcinolone can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Triazolam The serum concentration of Triazolam can be decreased when it is combined with Enzalutamide. Approved, Investigational Trimethadione The serum concentration of Trimethadione can be decreased when it is combined with Enzalutamide. Approved Trimethoprim The serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide. Approved, Vet Approved Trimipramine The serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide. Approved Troglitazone The serum concentration of Troglitazone can be decreased when it is combined with Enzalutamide. Investigational, Withdrawn Troleandomycin The serum concentration of Troleandomycin can be decreased when it is combined with Enzalutamide. Approved Udenafil The serum concentration of Udenafil can be decreased when it is combined with Enzalutamide. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Enzalutamide. Approved Ulobetasol The serum concentration of Ulobetasol can be decreased when it is combined with Enzalutamide. Approved Valbenazine The serum concentration of Valbenazine can be decreased when it is combined with Enzalutamide. Approved, Investigational Valdecoxib The serum concentration of Valdecoxib can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Vandetanib The serum concentration of Vandetanib can be decreased when it is combined with Enzalutamide. Approved Vanoxerine The serum concentration of Vanoxerine can be decreased when it is combined with Enzalutamide. Investigational Vardenafil The serum concentration of Vardenafil can be decreased when it is combined with Enzalutamide. Approved Velpatasvir The serum concentration of Velpatasvir can be decreased when it is combined with Enzalutamide. Approved, Investigational Vemurafenib The serum concentration of Vemurafenib can be decreased when it is combined with Enzalutamide. Approved Venetoclax The serum concentration of Venetoclax can be decreased when it is combined with Enzalutamide. Approved, Investigational Venlafaxine The serum concentration of Venlafaxine can be decreased when it is combined with Enzalutamide. Approved Verapamil The serum concentration of Verapamil can be decreased when it is combined with Enzalutamide. Approved Vicriviroc The serum concentration of Vicriviroc can be decreased when it is combined with Enzalutamide. Investigational Vilanterol The serum concentration of Vilanterol can be decreased when it is combined with Enzalutamide. Approved Vilazodone The serum concentration of Vilazodone can be decreased when it is combined with Enzalutamide. Approved Vinblastine The serum concentration of Vinblastine can be decreased when it is combined with Enzalutamide. Approved Vincristine The serum concentration of Vincristine can be decreased when it is combined with Enzalutamide. Approved, Investigational Vindesine The serum concentration of Vindesine can be decreased when it is combined with Enzalutamide. Approved, Investigational Vinflunine The serum concentration of Vinflunine can be decreased when it is combined with Enzalutamide. Approved, Investigational Vinorelbine The serum concentration of Vinorelbine can be decreased when it is combined with Enzalutamide. Approved, Investigational Vismodegib The serum concentration of Vismodegib can be decreased when it is combined with Enzalutamide. Approved, Investigational Vorapaxar The serum concentration of Vorapaxar can be decreased when it is combined with Enzalutamide. Approved Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Enzalutamide. Approved, Investigational Vortioxetine The serum concentration of Vortioxetine can be decreased when it is combined with Enzalutamide. Approved, Investigational Voxilaprevir The serum concentration of Voxilaprevir can be decreased when it is combined with Enzalutamide. Approved, Investigational Warfarin The serum concentration of Warfarin can be decreased when it is combined with Enzalutamide. Approved Yohimbine The serum concentration of Yohimbine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Vet Approved Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Enzalutamide. Approved, Investigational Zalcitabine The serum concentration of Zalcitabine can be decreased when it is combined with Enzalutamide. Approved, Investigational Zaleplon The serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide. Approved, Illicit, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Enzalutamide. Approved Zileuton The serum concentration of Zileuton can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Ziprasidone The serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide. Approved Zolpidem The serum concentration of Zolpidem can be decreased when it is combined with Enzalutamide. Approved Zomepirac The serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide. Withdrawn Zonisamide The serum concentration of Zonisamide can be decreased when it is combined with Enzalutamide. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be decreased when it is combined with Enzalutamide. Approved Zotepine The serum concentration of Zotepine can be decreased when it is combined with Enzalutamide. Approved, Investigational, Withdrawn Zuclopenthixol The serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC: NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22. [PubMed:23699654]
- External Links
- KEGG Drug
- D10218
- PubChem Compound
- 15951529
- PubChem Substance
- 175427141
- ChemSpider
- 13093347
- BindingDB
- 50425732
- ChEBI
- 68534
- ChEMBL
- CHEMBL1082407
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Enzalutamide
- ATC Codes
- L02BB04 — Enzalutamide
- AHFS Codes
- 10:00.00 — Antineoplastic Agents
- FDA label
- Download (393 KB)
- MSDS
- Download (89.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral 40 mg Capsule Oral 40 mg/1 - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US8183274 No 2006-05-15 2026-05-15 US US9126941 No 2006-05-15 2026-05-15 US US7709517 No 2007-08-13 2027-08-13 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble FDA label - Predicted Properties
Property Value Source Water Solubility 0.00136 mg/mL ALOGPS logP 3.75 ALOGPS logP 4.16 ChemAxon logS -5.5 ALOGPS pKa (Strongest Acidic) 13.05 ChemAxon pKa (Strongest Basic) -1.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 76.44 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 113.48 m3·mol-1 ChemAxon Polarizability 42.71 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9356 Blood Brain Barrier + 0.8514 Caco-2 permeable + 0.5219 P-glycoprotein substrate Non-substrate 0.7609 P-glycoprotein inhibitor I Inhibitor 0.6464 P-glycoprotein inhibitor II Inhibitor 0.5693 Renal organic cation transporter Non-inhibitor 0.899 CYP450 2C9 substrate Non-substrate 0.7447 CYP450 2D6 substrate Non-substrate 0.8061 CYP450 3A4 substrate Substrate 0.5589 CYP450 1A2 substrate Non-inhibitor 0.5613 CYP450 2C9 inhibitor Inhibitor 0.7126 CYP450 2D6 inhibitor Non-inhibitor 0.9148 CYP450 2C19 inhibitor Inhibitor 0.6882 CYP450 3A4 inhibitor Inhibitor 0.6184 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6711 Ames test Non AMES toxic 0.683 Carcinogenicity Non-carcinogens 0.7232 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4319 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9911 hERG inhibition (predictor II) Inhibitor 0.7079
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-014i-0321900000-b1c610c4a717fdea030e
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenylimidazolidines. These are polycyclic compounds containing an imidazoline substituted by a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azolidines
- Sub Class
- Imidazolidines
- Direct Parent
- Phenylimidazolidines
- Alternative Parents
- Trifluoromethylbenzenes / 2-halobenzoic acids and derivatives / Alpha amino acids and derivatives / N-phenylthioureas / Benzamides / Benzoyl derivatives / Benzonitriles / Fluorobenzenes / Aryl fluorides / Imidazolidinones show 11 more
- Substituents
- Phenylimidazolidine / Alpha-amino acid or derivatives / Trifluoromethylbenzene / N-phenylthiourea / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Benzonitrile / Benzoyl show 29 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- benzamides, nitrile, imidazolidinone, monofluorobenzenes, (trifluoromethyl)benzenes, thiocarbonyl compound (CHEBI:68534)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
Drug created on June 04, 2013 23:12 / Updated on April 23, 2018 23:12